These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 18781896)
1. Clinical use of therapies targeting tumor vasculature and stroma. Davis ID; Desai J Curr Cancer Drug Targets; 2008 Sep; 8(6):498-508. PubMed ID: 18781896 [TBL] [Abstract][Full Text] [Related]
2. Targeting the tumor stroma in cancer therapy. Anton K; Glod J Curr Pharm Biotechnol; 2009 Feb; 10(2):185-91. PubMed ID: 19199950 [TBL] [Abstract][Full Text] [Related]
3. Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Abu Lila AS; Ishida T; Kiwada H Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711 [TBL] [Abstract][Full Text] [Related]
4. Tumor-stromal cell interactions and opportunities for therapeutic intervention. Udagawa T; Wood M Curr Opin Pharmacol; 2010 Aug; 10(4):369-74. PubMed ID: 20638903 [TBL] [Abstract][Full Text] [Related]
5. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Bouzin C; Feron O Drug Resist Updat; 2007 Jun; 10(3):109-20. PubMed ID: 17452119 [TBL] [Abstract][Full Text] [Related]
6. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Shojaei F; Ferrara N Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057 [TBL] [Abstract][Full Text] [Related]
7. Role of the tumor stroma in resistance to anti-angiogenic therapy. Huijbers EJ; van Beijnum JR; Thijssen VL; Sabrkhany S; Nowak-Sliwinska P; Griffioen AW Drug Resist Updat; 2016 Mar; 25():26-37. PubMed ID: 27155374 [TBL] [Abstract][Full Text] [Related]
8. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Raza A; Franklin MJ; Dudek AZ Am J Hematol; 2010 Aug; 85(8):593-8. PubMed ID: 20540157 [TBL] [Abstract][Full Text] [Related]
10. Abnormal tumor vasculatures and bone marrow-derived pro-angiogenic cells in cancer. Mizukami Y; Sasajima J; Ashida T; Kohgo Y Int J Hematol; 2012 Feb; 95(2):125-30. PubMed ID: 22311464 [TBL] [Abstract][Full Text] [Related]
11. Effects of photodynamic therapy on tumor stroma. Peng Q; Nesland JM Ultrastruct Pathol; 2004; 28(5-6):333-40. PubMed ID: 15764581 [TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibitors. Drug selectivity and target specificity. Kesisis G; Broxterman H; Giaccone G Curr Pharm Des; 2007; 13(27):2795-809. PubMed ID: 17897024 [TBL] [Abstract][Full Text] [Related]
13. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility. Close A Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926 [TBL] [Abstract][Full Text] [Related]
14. Targeting the tumor stroma with peroxisome proliferator activated receptor (PPAR) agonists. Bundscherer A; Reichle A; Hafner C; Meyer S; Vogt T Anticancer Agents Med Chem; 2009 Sep; 9(7):816-21. PubMed ID: 19594413 [TBL] [Abstract][Full Text] [Related]